A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Effects of MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Airway Eosinophils in Adults With Atopic Asthma

NCT00659659 Phase 1 COMPLETED

Evaluate the safety and tolerability of MEDI-563 in adults with asthma and the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies

Details

Lead sponsor	MedImmune LLC
Phase	Phase 1
Status	COMPLETED
Enrolment	27
Start date	2008-01
Completion	2011-03

Conditions

• Asthma

Interventions

• MEDI-563
• MEDI-563
• Placebo Comp.
• Placebo

Primary outcomes

• Evaluate the safety and tolerability of MEDI-563 in adults with atopic asthma and evaluate the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies 28 days after completion of dosing in adults with atopic asthma. — Study Day 84 or Day 140 - (dose-driven)

Countries

United States, Canada